Lung Cancer

Everett E. Vokes, MD, discusses remaining questions in stage III non–small cell lung cancer following the PACIFIC results.

Allison Campbell, MD, PhD, discusses the synergy between immune checkpoint inhibitors and radiation therapy and the challenges facing ongoing clinical development.

Lawrence E. Feldman, MD, discusses utilizing prophylactic cranial irradiation in limited-stage and extensive-stage small cell lung cancer.

Jeremy Segal, MD, PhD, discusses pathologic considerations in non–small cell lung cancer and the evolving role of molecular testing.

A growing appreciation of the immunomodulatory properties of radiation therapy (RT) and their role in the rare, but highly sought-after “abscopal effect”—whereby localized RT elicits systemic antitumor effects—is fueling excitement in the radiation oncology field.

Lawrence E. Feldman, MD, discusses the impact of the phase III data of the IMpower133 and CASPIAN trials, ongoing trials, and other updates in small cell lung cancer treatment.

Zofia Piotrowska, MD, MHS, discusses treatment strategies for EGFR-mutant non–small cell lung cancer.

Azadeh Namakydoust, MD, discusses recent advancements in lung cancer and what the future holds.

Azadeh Namakydoust, MD, FACP, thoracic oncologist, Memorial Sloan Kettering Cancer Center, discusses the use of next-generation sequencing (NGS) in lung cancer.

Benjamin P. Levy, MD, discusses the identification of molecular drivers in non–small cell lung cancer.

Mark G. Kris, MD, discusses the impact of targeted therapy in patients with EGFR-mutant NSCLC and the encouraging activity that has been reported with checkpoint inhibitors in advanced squamous disease.

Taofeek K. Owonikoko, MD, PhD, discusses current standard of care treatments for patients with small cell lung cancer.

Karen Kelly, MD, discusses how to determine treatment after patients with lung cancer progress on TKIs.

Isabel Preeshagul, DO, MBS, discusses encouraging updates with molecular drivers in non–small cell lung cancer and her advice to community oncologists treating patients.

Mary J. Fidler, MD, discusses the results of the phase III RELAY trial in treatment-naïve patients with EGFR-mutant non–small cell lung cancer.

Rapid advancements are dramatically changing the lung cancer treatment landscape, creating challenges across the spectrum of care.

Mark G. Kris, MD, discusses the ongoing search for additional biomarkers in advanced squamous non­–small cell lung cancer.

Brendon Stiles, MD, discusses considerations for surgery in lung cancer.

Michael D. Offin, MD, discusses targeted agents in MET- and RET-altered non–small cell lung cancer.

Suresh S. Ramalingam, MD, FASCO, highlights current and emerging therapies for 6 key actionable driver mutations in non–small cell lung cancer.

Hossein Borghaei, DO, MS, discusses the search for biomarkers in lung cancer.

Balazs Halmos, MD, MS, discusses actionable biomarkers in patients with oncogene-driven non–small cell lung cancer.

Fred R. Hirsch, MD, PhD, discusses the expansion of molecular testing in lung cancer.

Plasma genotyping is the next big thing in non–small cell lung cancer, and it's already impacting clinical practice.

Zofia Piotrowska, MD, MHS, discusses the role of osimertinib in treating patients with EGFR-mutant non–small cell lung cancer and how it compares with other therapeutic options in that space.